Literature DB >> 30737810

Case report by Toce and co-authors: Have all the reasons for poor morphine glucuronidation been addressed?

Moshe Finel1, Erkka Järvinen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30737810      PMCID： PMC6422727          DOI： 10.1111/bcp.13868

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  9 in total

1.  Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring.

Authors:  John K Fallon; Hendrik Neubert; Ruth Hyland; Theunis C Goosen; Philip C Smith
Journal:  J Proteome Res       Date:  2013-09-26       Impact factor: 4.466

2.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes.

Authors:  Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2017-12       Impact factor: 8.739

3.  Prolonged central apnoea after intravenous morphine administration in a 12-year-old male with a UGT1A1 loss-of-function polymorphism.

Authors:  Michael S Toce; Hyun Kim; Sarita Chung; Baruch S Krauss
Journal:  Br J Clin Pharmacol       Date:  2018-11-12       Impact factor: 4.335

4.  Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation.

Authors:  Verawan Uchaipichat; Pritsana Raungrut; Nuy Chau; Benjamas Janchawee; Allan M Evans; John O Miners
Journal:  Drug Metab Dispos       Date:  2011-05-06       Impact factor: 3.922

Review 5.  Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype.

Authors:  A Kadakol; S S Ghosh; B S Sappal; G Sharma; J R Chowdhury; N R Chowdhury
Journal:  Hum Mutat       Date:  2000-10       Impact factor: 4.878

6.  Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7.

Authors:  Andrew N Stone; Peter I Mackenzie; Aleksandra Galetin; J Brian Houston; John O Miners
Journal:  Drug Metab Dispos       Date:  2003-09       Impact factor: 3.922

7.  Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism.

Authors:  Michael H Court; Soundarajan Krishnaswamy; Qin Hao; Su X Duan; Christopher J Patten; Lisa L Von Moltke; David J Greenblatt
Journal:  Drug Metab Dispos       Date:  2003-09       Impact factor: 3.922

8.  Optimized methods for targeted peptide-based quantification of human uridine 5'-diphosphate-glucuronosyltransferases in biological specimens using liquid chromatography-tandem mass spectrometry.

Authors:  Yuichiro Sato; Masanori Nagata; Kazuhiro Tetsuka; Kouichi Tamura; Aiji Miyashita; Akio Kawamura; Takashi Usui
Journal:  Drug Metab Dispos       Date:  2014-03-04       Impact factor: 3.922

9.  Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties.

Authors:  Shuji Ohno; Kiyoshi Kawana; Shizuo Nakajin
Journal:  Drug Metab Dispos       Date:  2008-01-10       Impact factor: 3.922
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.